Similarly, in clinical trial SARC028, only one of the 10 SS patients responded to pembrolizumab [14], while in another study of anti-CTLA4 (ipilimumab) treatment, all six SS patients failed to respond [64]. The gene discussed is CTLA4; the disease is synovial sarcoma.